Skip to main content
SpringerLink
Log in

Pharmacokinetic Study of Esomeprazole in the Elderly

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Objective

Esomeprazole is the first proton pump inhibitor to be developed as an optical isomer for the treatment of patients with acid-related diseases. The aim of this study was to examine the pharmacokinetics and tolerability of esomeprazole in the elderly, relative to middle-aged patients with gastro-oesopha-geal reflux disease (GORD).

Design

Nonblinded single-centre pharmacokinetic study with historical control group.

Patients and Participants

14 healthy elderly volunteers [mean age 74 (range 71 to 80) years].

Methods

Participants received treatment with esomeprazole 40mg once daily for 5 days, with 24-hour blood sampling on days 1 and 5. The total area under the plasma concentration-time curve (AUC∞), maximum plasma drug concentration (Cmax), terminal elimination half-life (t1/2z) and time to Cmax (tmax) were determined for the parent drug and its hydroxy and sulphone metabolites. AUC∞ and Cmax data were compared with those in an historical group of 36 middle-aged patients [mean age 45 (range 29 to 58) years] with GORD, treated with an identical dosage of esomeprazole for 5 days.

Results

A total of 13 volunteers completed the study. On day 5, the mean plasma AUC∞ of esomeprazole was 16.0 µmol · h/L, Cmaxwas 5.6 µmol/L, tmax was 1.5 hours and t1/2z was 1.7 hours. The AUC∞ and Cmax values for the parent drug were 2- and 1.5-fold higher on day 5 compared with day 1. AUC∞ and Cmax values for the sulphone metabolite increased to a slightly greater extent, and values for the hydroxy metabolite were unchanged. Ratios of the AUC∞ and Cmax values between elderly volunteers and patients with GORD were 1.25 [95% confidence interval (CI) 0.94, 1.67] and 1.18 (0.91, 1.52), respectively. Esomeprazole was well tolerated and there were no safety concerns.

Conclusions

The AUC∞ and Cmax values in the elderly were not significantly different from those obtained in a group of middle-aged patients. The difference for AUC∞ was 25% (95% CI −6% to +67%). Esomeprazole has a wide therapeutic window and our results do not indicate that dosage adjustment should be necessary in the elderly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Table II

Similar content being viewed by others

References

  1. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998; 56: 307–35

    Article  PubMed  CAS  Google Scholar 

  2. Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61: 331–9

    Article  PubMed  CAS  Google Scholar 

  3. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9–28

    Article  PubMed  CAS  Google Scholar 

  4. Breuel HP, Hartmann M, Bondy S, et al. Pantoprazole in the elderly: no dose-adjustment [abstract]. Gut 1994; Suppl. 4: 77

    Google Scholar 

  5. Flouvat B, Delhotal-Landes B, Cournot A, et al. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol 1993; 36: 467–9

    Article  PubMed  CAS  Google Scholar 

  6. Landahl S, Andersson T, Larsson ME, et al. Pharmacokinetic study of omeprazole in elderly healthy volunteers. Clin Pharmacokinet 1992; 23: 469–76

    Article  PubMed  CAS  Google Scholar 

  7. Lind T, Rydberg L, Kylebäck A, et al. Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-esophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861–7

    Article  PubMed  CAS  Google Scholar 

  8. Äbelö A, Andersson TB, Antonsson M, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 966–72

    PubMed  Google Scholar 

  9. Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatography 1984; 309: 347–56

    Article  Google Scholar 

  10. Hussein Z, Granneman GR, Mukherji D, et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 1993; 36: 391–8

    Article  PubMed  CAS  Google Scholar 

  11. Laurent AL, Merritt GJ, Setoyama T, et al. Rabeprazole: pharmacokinetics and safety in the elderly. Clin Geriatr 1999; 7: 27–33

    Google Scholar 

  12. Delhotal-Landes B, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995; 28: 458–70

    Article  Google Scholar 

  13. Barclay ML, Begg EJ, Robson RA, et al. Lansoprazole pharmacokinetics differ in patients with esophagitis compared to healthy volunteers. Aliment Pharmacol Ther 1999; 13: 1215–9

    Article  PubMed  CAS  Google Scholar 

  14. Ching MS, Mihaly GW, Angus PW, et al. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. Br J Clin Pharmacol 1991; 31: 166–70

    Article  PubMed  CAS  Google Scholar 

  15. Hassan-Alin M, Andersson T, Bredberg E, et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000; 56: 665–70

    Article  PubMed  CAS  Google Scholar 

  16. Abernethy DR, Greenblatt DJ. Impairment of lidocaine clearance in elderly male subjects. J Cardiovasc Pharmacol 1983; 5: 1093–6

    Article  PubMed  CAS  Google Scholar 

  17. Nation RL, Triggs EJ, Selig M. Lignocaine kinetics in cardiac patients and aged subjects. Br J Clin Pharmacol 1977; 4: 439–48

    Article  PubMed  CAS  Google Scholar 

  18. Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521–30

    Article  PubMed  CAS  Google Scholar 

  19. Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994; 37: 597–604

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Astra-Zeneca R&D Mölndal, S-431 83, Mölndal, Sweden

    Göran Hasselgren, Mohammed Hassan-Alin, Catharina Claar-Nilsson & Kerstin Röhss

  2. AstraZeneca LP, Wayne, Pennsylvania, USA

    Tommy Andersson

Authors
  1. Göran Hasselgren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammed Hassan-Alin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tommy Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Catharina Claar-Nilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kerstin Röhss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Göran Hasselgren.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hasselgren, G., Hassan-Alin, M., Andersson, T. et al. Pharmacokinetic Study of Esomeprazole in the Elderly. Clin Pharmacokinet 40, 145–150 (2001). https://doi.org/10.2165/00003088-200140020-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200140020-00006

Keywords

Search

Navigation